NeuroneticsSTIM
About: Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Employees: 716
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
52% more capital invested
Capital invested by funds: $8.05M [Q3] → $12.2M (+$4.16M) [Q4]
6% less funds holding
Funds holding: 48 [Q3] → 45 (-3) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
11.38% less ownership
Funds ownership: 34.92% [Q3] → 23.54% (-11.38%) [Q4]
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Canaccord Genuity William Plovanic 38% 1-year accuracy 18 / 48 met price target | 83%upside $8 | Buy Maintained | 5 Mar 2025 |
Citizens Capital Markets Daniel Stauder 18% 1-year accuracy 2 / 11 met price target | 60%upside $7 | Market Outperform Maintained | 5 Mar 2025 |
Financial journalist opinion









